Bausch Health Companies Inc. (BHC)
Pre-Market:
| Previous Close | 5.94 |
| Open | 5.96 |
| Bid | 5.21 x 1800 |
| Ask | 5.90 x 4000 |
| Day's Range | 5.60 - 5.97 |
| 52 Week Range | 4.00 - 29.59 |
| Volume | |
| Avg. Volume | 7,466,216 |
| Market Cap | 2.08B |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | 41.07 |
| EPS (TTM) | 0.14 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | 15.35 |
- The Motley Fool
3 Top Stocks You Can Still Buy for Under $20 a Share
Canopy Growth stock (TSX:WEED)(NASDAQ:CGC) and these two others are incredible investments to consider as we continue to move out of this market correction. The post 3 Top Stocks You Can Still Buy for Under $20 a Share appeared first on The Motley Fool Canada.
- Zacks
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
- CNW Group
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court of Delaware has issued a decision in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. finding certain XIFAXAN® (rifaximin) 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid. As previously stated, the Company will
